This study, called ASAP, aims to understand the genetic makeup of cancers and pre-cancerous conditions in patients receiving care within the Avera healthcare system. Researchers will use comprehensive genomic profiling (looking at your genes) to identify the underlying genetic changes that drive these conditions. This involves testing tumor tissue and/or blood using next-generation sequencing (a way to read DNA). They will also perform pharmacogenomic testing to see how your genes might affect your response to medications, which could help optimize your treatment. You may be able to join if you are at least 18 years old and are being evaluated for a pre-cancerous condition or have a cancer diagnosis. The study hopes to enroll 25,000 participants and will measure how many patients receive comprehensive molecular profiling, are referred for genetic testing for their family members, and are referred for clinical trials targeting specific genetic changes, all over a 5-year period.

Study design

This is an observational study, meaning researchers will collect information without giving any specific interventions. It plans to enroll 25,000 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Researchers will track certain outcomes for 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.